State Street
RLAY icon

State Street’s Relay Therapeutics RLAY Stock Holding History

State Street’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$189M Buy
10,125,381
+3,891,836
+62% +$56.5M 0.01% 1077
2026
Q1 		$62M Sell
6,233,545
-192,566
-3% -$1.72M ﹤0.01% 1629
2025
Q4 		$54.4M Buy
6,426,111
+1,360,121
+27% +$9.71M ﹤0.01% 1695
2025
Q3 		$26.4M Sell
5,065,990
-136,801
-3% -$522K ﹤0.01% 2091
2025
Q2 		$18M Buy
5,202,791
+43,599
+0.8% +$130K ﹤0.01% 2245
2025
Q1 		$13.5M Sell
5,159,192
-120,534
-2% -$472K ﹤0.01% 2341
2024
Q4 		$21.8M Buy
5,279,726
+979,510
+23% +$5.33M ﹤0.01% 2185
2024
Q3 		$30.4M Buy
4,300,216
+51,810
+1% +$387K ﹤0.01% 1965
2024
Q2 		$27.7M Sell
4,248,406
-1,772,582
-29% -$12.1M ﹤0.01% 1993
2024
Q1 		$50M Buy
6,020,988
+1,117,410
+23% +$10.9M ﹤0.01% 1731
2023
Q4 		$54M Sell
4,903,578
-3,011
-0.1% -$25.4K ﹤0.01% 1663
2023
Q3 		$41.3M Sell
4,906,589
-2,304,208
-32% -$24.8M ﹤0.01% 1736
2023
Q2 		$90.6M Buy
7,210,797
+1,330,516
+23% +$16.5M ﹤0.01% 1287
2023
Q1 		$96.8M Sell
5,880,281
-384,216
-6% -$6.89M 0.01% 1208
2022
Q4 		$93.6M Buy
6,264,497
+2,596,427
+71% +$49.7M 0.01% 1195
2022
Q3 		$82.1M Sell
3,668,070
-1,110,349
-23% -$24.4M 0.01% 1246
2022
Q2 		$80M Buy
4,778,419
+1,524,727
+47% +$32.7M ﹤0.01% 1324
2022
Q1 		$97.4M Buy
3,253,692
+67,170
+2% +$1.63M ﹤0.01% 1317
2021
Q4 		$97.9M Buy
3,186,522
+504,846
+19% +$16M ﹤0.01% 1313
2021
Q3 		$84.6M Buy
2,681,676
+463,516
+21% +$15.6M ﹤0.01% 1410
2021
Q2 		$81.2M Buy
2,218,160
+202,584
+10% +$6.68M ﹤0.01% 1467
2021
Q1 		$69.7M Buy
2,015,576
+688,871
+52% +$29.9M ﹤0.01% 1499
2020
Q4 		$55.1M Buy
1,326,705
+848,817
+178% +$38.4M ﹤0.01% 1575
2020
Q3 		$20.4M Buy
+477,888
New +$18.2M ﹤0.01% 2030

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

State Street's RLAY Position: Q2 2026 in Review

State Street increased its Relay Therapeutics (RLAY) stake by 62% in Q2 2026, buying an estimated $56.5M and bringing the position to 10,125,381 shares worth $189M. The position accounts for 0.01% of the portfolio, ranked #1077.

State Street first reported a position in RLAY in Q3 2020 and has held it in 24 quarters since. 260 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • State Street held 10,125,381 shares of Relay Therapeutics worth $189M as of Q2 2026.
  • State Street bought 3,891,836 Relay Therapeutics shares in Q2 2026, an estimated $56.5M.
  • Relay Therapeutics made up 0.01% of State Street's portfolio in Q2 2026, its #1077 holding.
  • State Street first reported a position in Relay Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • 260 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.